Calcium Pyrophosphate Deposition Disease (Pseudogout)

• Pyrophosphate metabolism and crystal nucleation: Pyrophosphate (PPi) is generated intracellularly as a byproduct of nucleotide metabolism and ATP hydrolysis. Under normal circumstances, pyrophosphatases regulate PPi levels to prevent crystal formation. In CPPD, defects in pyrophosphatase activity, altered ATP metabolism, or elevated local PPi concentrations lead to supersaturation in the extracellular matrix and synovial fluid. CPPD crystals preferentially nucleate in hyaline and fibrocartilage due to the presence of proteoglycans (particularly chondroitin sulfate and keratan sulfate) that serve as nucleation sites. Once nucleated, calcium pyrophosphate dihydrate crystals form rhomboid or rod-shaped monocrystalline structures that become embedded in cartilage matrix and can remain quiescent for years.

• Crystal shedding and innate immune activation: The acute inflammatory flares of pseudogout occur when CPPD crystals are released from articular cartilage into the synovial space—often triggered by joint trauma, surgery, or acute illness. Soluble CPPD crystals are phagocytosed by synovial macrophages and lining cells, initiating a pattern recognition receptor response. This triggers activation of the NLRP3 inflammasome, a cytoplasmic protein complex that recognizes danger-associated molecular patterns. Inflammasome activation leads to cleavage of procaspase-1 and subsequent processing of pro-interleukin-1β (pro-IL-1β) and pro-IL-18 into their active forms. Mature IL-1β is the primary cytokine driving the acute inflammatory cascade, inducing production of additional proinflammatory mediators (IL-6, IL-8, TNF-α, prostaglandin E2), recruitment of neutrophils, and upregulation of adhesion molecules on endothelial cells.

• Neutrophil recruitment and synovial inflammation: Activated macrophages and synovial lining cells release chemotactic factors that recruit massive numbers of neutrophils into the synovial space, achieving fluid cell counts of 2,000–50,000 cells/μL (predominantly neutrophils). Neutrophils themselves phagocytose CPPD crystals, further amplifying inflammasome activation and IL-1β production in a positive feedback loop. This explosive neutrophilic infiltration causes the characteristic acute synovitis with pain, swelling, erythema, and effusion. Unlike acute gout (where monosodium urate crystals are needle-shaped and predominantly intracellular), CPPD crystals are more easily found extracellularly and may persist in synovial fluid even after inflammation resolves.

• Cartilage degradation and chronic changes: Chronic CPPD deposition leads to progressive cartilage damage through multiple mechanisms. IL-1β upregulates matrix metalloproteinases (MMP-1, MMP-3, MMP-8, MMP-13) in both chondrocytes and synovial fibroblasts, promoting collagen and proteoglycan breakdown. Additionally, IL-1β suppresses the synthesis of tissue inhibitors of metalloproteinases (TIMPs), shifting the protease/antiprotease balance toward degradation. The continuous presence of CPPD crystals in cartilage creates chronic low-grade inflammation, similar to osteoarthritis but with superimposed acute flares. This explains why CPPD often manifests as an accelerated or atypical osteoarthritis pattern with progressive joint space narrowing and osteophyte formation.

• Genetic and metabolic predisposition factors: Familial CPPD with autosomal dominant inheritance patterns (5–10% of cases) has been associated with mutations in the ANKH gene (encoding an inorganic pyrophosphate transporter), which increases PPi export and predisposes to crystal deposition. Acquired forms are associated with metabolic derangements (hypercalcemia, hyperphosphatemia) that increase the calcium × phosphate product and promote crystal precipitation. Hypomagnesemia, hypokalemia, and hemochromatosis also disturb pyrophosphate regulation. Aging causes accumulation of calcium and alterations in cartilage structure (decreased water content, increased mineralization), explaining the age-related prevalence increase.

• Primary (idiopathic) CPPD: Accounts for approximately 90% of cases and is associated with advancing age, female sex (slight female predominance), and possibly genetic predisposition. No identifiable metabolic abnormality is present. This is the most common presentation and is essentially a disease of the elderly; the strong age association suggests that cumulative cartilage changes and altered calcium/phosphate handling occur with senescence.

• Secondary CPPD associated with metabolic disease: Hyperparathyroidism is the classic metabolic association, causing hypercalcemia and hyperphosphatemia that promote CPPD crystallization. Patients present with pseudogout attacks and should be screened for elevated PTH and serum calcium. Hemochromatosis (hereditary or secondary iron overload) promotes CPPD through unclear mechanisms but frequently causes polyarticular pseudogout and chronic arthropathy; iron deposition in synovial tissue may impair antioxidant defenses and promote inflammation. Hypothyroidism is associated with CPPD, possibly through altered pyrophosphate metabolism. Hypomagnesemia and hypokalemia impair pyrophosphatase activity and predispose to CPPD; diuretic use (especially loop and thiazide diuretics) causing chronic electrolyte depletion is an important risk factor. Hypophosphatasia (alkaline phosphatase deficiency) paradoxically causes CPPD because pyrophosphate accumulates due to lack of enzymatic breakdown.

• Secondary CPPD associated with joint damage: Osteoarthritis is the most common joint condition associated with CPPD; crystals form in damaged cartilage. Rheumatoid arthritis and other inflammatory arthropathies can coexist with CPPD ("pseudogout superimposed on rheumatoid arthritis"), creating diagnostic confusion. Neuropathic joints (Charcot joints from diabetes, tabes dorsalis, or syringomyelia) frequently develop CPPD deposits due to cartilage destruction. Post-traumatic arthritis and meniscectomy increase local CPPD risk.

• Triggering factors for acute attacks: Acute CPPD crystal release and pseudogout flares are classically triggered by acute illness (myocardial infarction, stroke, sepsis, surgery), joint trauma or aspiration, diuretic use (volume depletion and electrolyte shifts), and dehydration. This distinguishes CPPD clinically because acute medical events frequently unmask the disease.

• Acute pseudogout attacks (classic presentation): The episodic acute form mimics gout and represents the most dramatic presentation. Patients experience sudden onset of severe joint pain, typically in large joints (knee most common, followed by wrist, shoulder, ankle, elbow, hip). The attack reaches maximum intensity over 24–48 hours and is characterized by exquisite pain, marked swelling, erythema, and warmth. Systemic symptoms may include low-grade fever (101–102°F), malaise, and leukocytosis (WBC 10,000–15,000 cells/μL), sometimes mimicking sepsis. Attacks typically last 3–14 days even without treatment, distinguishing them from the potentially chronic progression of untreated gout. Women and elderly patients are more commonly affected.

• Chronic pseudogout (pseudorheumatoid arthritis pattern): Some patients develop persistent polyarticular inflammation without discrete acute flares. This pattern presents with chronic morning stiffness (often >1 hour), symmetric polyarticular swelling (wrists, hands, knees, shoulders), and progressive functional decline. This variant is clinically deceptive because it closely mimics rheumatoid arthritis; the key differentiator is negative rheumatoid factor and anti-CCP antibodies, presence of CPPD crystals on synovial fluid analysis, and characteristic radiographic findings.

• Asymptomatic chondrocalcinosis: Up to 60% of patients with radiographic evidence of chondrocalcinosis are asymptomatic and never develop clinical disease. This is an incidental finding on imaging performed for other reasons and requires no specific treatment beyond monitoring.

• Progressive osteoarthritis-like disease (pseudo-osteoarthritis or accelerated OA): Some patients develop progressive joint destruction with large osteophytes, joint space narrowing, and functional impairment in atypical distribution (shoulders, wrists, knees symmetrically). This pattern differs from typical osteoarthritis by its earlier age of onset, more rapid progression, and polyarticular distribution.

• Acute monoarticular or oligoarticular arthritis: Most commonly affects the knee, but wrist and shoulder arthritis occurs frequently. The affected joint demonstrates visible swelling, warmth, erythema, restricted range of motion (painful especially at endpoints), and positive findings on imaging (effusion, synovitis on ultrasound or MRI).

• Physical examination findings: Affected joints show obvious swelling (effusion), erythema, warmth, and tenderness to palpation and motion. Range of motion is restricted by pain and stiffness. Some patients demonstrate tophi-like deposits of monosodium urate in soft tissues (distinguishing feature from gout). Chronic disease presents with firm, bony swelling (bony protuberances), crepitus with motion, and restricted range of motion.

• Systemic constitutional symptoms: Low-grade fever, malaise, anorexia, and fatigue may accompany acute attacks, occasionally causing confusion with systemic infection or malignancy in elderly patients.

• Synovial fluid analysis (definitive diagnostic test): Arthrocentesis is the gold standard and must be performed during or shortly after an acute attack for optimal crystal visualization. Compensated polarized light microscopy demonstrates rhomboid or rod-shaped intracellular calcium pyrophosphate dihydrate crystals within synovial fluid white blood cells (neutrophils and macrophages). The crystals are positively birefringent (appear blue when parallel to the compensator) or non-birefringent depending on crystal orientation, distinguishing them from negatively birefringent monosodium urate crystals of gout. Synovial fluid is inflammatory with WBC counts typically 2,000–50,000 cells/μL, predominantly neutrophils (>90%), mimicking septic or gout-induced arthritis. Gram stain and culture must be negative to exclude bacterial infection, which can coexist with CPPD ("septic pseudogout"). No single finding is pathognomonic; the diagnosis requires clinical context (age, presentation, imaging) plus crystal identification.

• Synovial fluid characteristics:
• Cell count: 2,000–50,000 WBC/μL (ranges widely; can be <2,000 in chronic disease)
• Differential: >90% neutrophils in acute flares
• Gram stain/culture: Negative (to exclude coinfection)
• Glucose, protein: May be mildly elevated protein; glucose not typically measured
• Viscosity: May be decreased (inflammatory fluid)

• Serum chemistry and metabolic screening: All patients with CPPD should undergo screening for secondary causes. Serum calcium (total and ionized), phosphate, magnesium, alkaline phosphatase, and PTH should be measured to exclude hyperparathyroidism. Serum iron, ferritin, and transferrin saturation screen for hemochromatosis. Thyroid stimulating hormone (TSH) identifies hypothyroidism. Potassium and magnesium levels assess for electrolyte abnormalities from diuretic use. Abnormal findings warrant further workup.

• Radiographic findings—Chondrocalcinosis: Plain radiographs demonstrate fine, linear, or stippled radiodensities within articular cartilage (chondrocalcinosis) or fibrocartilage (particularly menisci in the knee, triangular cartilage of the wrist). The appearance is pathognomonic but not specific to acute disease; many asymptomatic elderly individuals have chondrocalcinosis. Distribution patterns:
• Hyaline cartilage calcification: Linear deposits in the joint space
• Fibrocartilage calcification: Deposits in menisci (knee) and triangular cartilage (wrist) are most frequent
• Typical sites: Knees (most common, 50% of cases), wrists (30%), shoulders, hips, symphysis pubis
• Associated changes: Joint space narrowing, osteophytes (osteoarthritis changes), subchondral cysts, and sclerosis in chronic disease

• Ultrasound and MRI: Ultrasound can visualize echogenic deposits within cartilage and confirm joint effusion and synovitis during acute attacks. MRI may show synovitis, effusion, and cartilage signal abnormalities but is not routinely needed for diagnosis.

• Diagnostic criteria (modified from various sources):

1. 1.Demonstration of CPPD crystals in synovial fluid (gold standard) OR
2. 2.Chondrocalcinosis on radiographs PLUS acute monoarticular or oligoarticular inflammation PLUS elevated synovial fluid WBC count AND negative Gram stain/culture AND absence of other definable disease (rheumatoid arthritis, gout, septic arthritis)

• Differential diagnosis considerations:
• Acute gout: Needle-shaped, negatively birefringent monosodium urate crystals; uric acid elevation; hyperuricemia history; responds rapidly to NSAIDs/colchicine
• Septic arthritis: Gram stain or culture positive; systemic toxicity; more severe; joint immobility; elevated blood lactate
• Rheumatoid arthritis: Positive rheumatoid factor/anti-CCP; symmetric small joint involvement; morning stiffness >1 hour; elevated ESR/CRP; systemic manifestations
• Acute bacterial endocarditis: New cardiac murmur; blood cultures positive; septic emboli in lungs/kidneys; persistent fever
• Viral arthritis: Recent viral prodrome; milder symptoms; self-limited course; negative crystal analysis
• Traumatic arthritis: Clear antecedent trauma; imaging shows fracture or ligamentous injury

• First-line acute attack management—NSAIDs: Nonsteroidal anti-inflammatory drugs (NSAIDs) are the preferred first-line therapy for acute pseudogout in patients without contraindications. High-dose indomethacin (50 mg three times daily for 3–7 days) is traditional, or naproxen (500 mg twice daily) or **ibu

Disease-related complications

• Coexistent septic arthritis (emergency): Crystals and bacteria can occupy the same joint, and crystal-induced inflammation does not exclude infection. Suspect it when fever is high, the patient is bacteremic or immunosuppressed, or the flare fails to defervesce on anti-inflammatory therapy. The signal is a positive Gram stain or culture — never let identified CPPD crystals stop you from culturing the fluid. Requires urgent drainage and antibiotics.
• **Chronic destructive arthropathy (pseudo-neuropathic joint)**: Persistent IL-1β–driven synovitis upregulates matrix metalloproteinases, producing severe subchondral collapse and fragmentation, classically at the knee, shoulder, or wrist, and sometimes indistinguishable radiographically from a Charcot joint. Signals: rapid loss of joint space with large subchondral cysts and deformity out of proportion to symptoms; often ends in arthroplasty.
• Crowned dens syndrome: CPPD deposition in the transverse ligament around the odontoid produces abrupt occipital/neck pain, neck rigidity, fever, and markedly elevated inflammatory markers, mimicking meningitis, giant cell arteritis, or polymyalgia rheumatica. Cervical spine CT showing periodontoid calcification is the confirmatory finding.
• Spinal involvement with myelopathy (emergency): Deposition in the ligamentum flavum or intervertebral discs can cause canal stenosis and cord compression — long-tract signs, gait change, or bowel/bladder dysfunction mandate urgent MRI and surgical consultation.
• Tendon and nerve complications: Crystal deposition in tendons predisposes to tenosynovitis and rupture; wrist and carpal deposition contributes to carpal tunnel syndrome.

Treatment-related complications

• NSAIDs: The elderly CPPD population is precisely the group at risk for GI bleeding, acute kidney injury, fluid retention, and cardiovascular events; EULAR recommendations on CPPD management advise gastroprotection and caution in renal or cardiac disease. Signals: melena, rising creatinine, decompensated heart failure.
• Colchicine toxicity: Cleared renally and via CYP3A4/P-glycoprotein — clarithromycin, diltiazem, or cyclosporine plus renal impairment can precipitate diarrhea, myopathy, and bone marrow suppression (a potentially fatal, emergency presentation). Dose reduction per FDA labeling is required in chronic kidney disease.
• Glucocorticoids: Systemic therapy causes hyperglycemia, delirium, and infection risk; intra-articular injection carries a small risk of iatrogenic septic arthritis and should not be given until infection is excluded.
• IL-1 blockade (anakinra, off-label): Increases risk of serious bacterial infection; withhold during active infection.

• The crystal pair: CPPD crystals are rhomboid/rod-shaped and positively birefringent (blue when parallel to the compensator); urate crystals are needle-shaped and negatively birefringent (yellow when parallel). Examiners test the color–orientation relationship, not just the shape.
• The single best next step in any acute hot joint is arthrocentesis with cell count, Gram stain, culture, and polarized microscopy — before imaging, before steroids. Crystals never rule out infection, and septic arthritis is the diagnosis you cannot afford to miss.
• Chondrocalcinosis is not a diagnosis: Linear cartilage calcification of the knee menisci, wrist triangular fibrocartilage, and symphysis pubis is common and asymptomatic in the elderly. A radiograph alone cannot establish that the current flare is pseudogout; the 2023 ACR/EULAR CPPD classification criteria still weight crystal identification most heavily.
• CPPD in a patient under roughly age 55–60, or with polyarticular/familial disease, mandates a metabolic workup: calcium, PTH, magnesium, phosphate, alkaline phosphatase, ferritin/transferrin saturation, TSH. The two examiners love: primary hyperparathyroidism and hereditary hemochromatosis.
• The hemochromatosis clue: pseudogout plus hook-like osteophytes at the 2nd and 3rd MCP joints plus bronze skin, diabetes, and hepatomegaly — check transferrin saturation and ferritin. Phlebotomy treats the iron overload but does not reverse the arthropathy.
• The classic trigger: a flare beginning days after surgery, myocardial infarction, stroke, or acute illness in a hospitalized elder — a swollen knee in the post-op patient is pseudogout until arthrocentesis proves otherwise.
• Neck pain with fever and high inflammatory markers in an elder: think crowned dens syndrome and get a cervical CT before committing to a diagnosis of meningitis or giant cell arteritis.
• Common distractor to avoid: there is no urate-lowering analogue for CPPD — allopurinol, febuxostat, and probenecid have no role, and no drug dissolves existing crystals. Management is anti-inflammatory (NSAIDs, colchicine, glucocorticoids, with low-dose colchicine for prophylaxis of recurrent attacks per EULAR CPPD recommendations).